Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.
Ninety patients with thalassaemia major were investigated for the occurrence of antinuclear antibodies (ANA), and those with ANA were tested for antibodies to histones (AHA). ANA were detected in 7 of 27 thalassemics on oral iron chelator L1, and in 2 of 63 thalassaemics not on L1 (p < 0.01). AHA were seen in 4 of 7 thalassemics receiving L1 with positive ANA, and in none of the 2 not receiving L1 (p < 0.03). Joint pains were seen in patients receiving L1, but in none of the patients not receiving L1. There was no correlation between hepatitis B or HIV positivity and presence of ANA or joint pains. While some amount of background ANA-positivity was found in patients with thalassaemia major, it was significantly more in patients receiving L1. Laboratory evidence of drug-induced lupus-like reaction was seen only in patients who received L1. In view of serious concerns about the safety of L1 and wide variations in the incidence and severity of adverse reactions reported by different sources, an urgent regulatory audit of all trial centres is essential.
Mehta
J
J
Blood Research Centre, Bombay.
Chablani
A
A
Reporter
R
R
Singhal
S
S
Mehta
B C
BC
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood*; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000276:immunology; D001803:Blood Transfusion; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006486:Hemosiderosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007501:Iron / Q000097:blood; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects*; D013789:Thalassemia / Q000276:immunology / Q000628:therapy*
D000974:Antibodies, Antinuclear; D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine